References
1. P Argani, et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol 2000 Jan;24(1):4-18.
2. R. Furtwangler, et al. Clear Cell Sarcomas of the Kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: A report of the SIOP Renal Tumour Study Group. Eur J Cancer 2013;49:3497-3506.
3. S. L. Gooskens, et al. Clear cell sarcoma of the kidney: A review. Eur J Cancer 2012;48:2219-2226.
4. Nita L. Seibel, et al. Effect of Duration of Treatment on Treatment Outcome for Patients With Clear-Cell Sarcoma of the Kidney: A Report From the National Wilms’ Tumor Study Group. J Clin Oncol 2004;22(3):468-73.
5. Nita L. Seibel, et al. Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study‐5 (NWTS‐5). Pediatr Blood Cancer 2019;66(1):e27450.
6. S. L. Gooskens, et al. Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study. Br J Cancer 2014;111:227-233.
7. Ueno-Yokohata H, et al. Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney. Nat Genet 2015;47(8):861-3.
8. Angshumoy Roy, et al. Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nature Commun 2015;6:8891.
9. O’Meara E, et al. Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. J Pathol 2012;227(1):72-80.
10. André Fehr, et al. YWHAE-FAM22 gene fusion in clear cell sarcoma of the kidney. J Pathol 2012;227:5-7.
11. Meng K Wong, et al. Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR–CCNB3 gene fusion. Histopathology 2018;72:320-329.
12. Masahiro Sekiguchi, et al. Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets. NPJ Precis Oncol. 2020;4:20.
13. Dang HX, et al. ClonEvol: clonal ordering and visualization in cancer sequencing. Ann Oncol 2017;28(12):3076-3082.
14. Shunsuke Kimura, et al. NOTCH 1 pathway activating mutations and clonal evolution in pediatric T‐cell acute lymphoblastic leukemia. Cancer Sci 2019;110:784-794.
15. Vlad C, et al. Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatr Blood Cancer 2008;50(2):246-9.
16. Mossner M, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood 2016;128(9):1246-59.
17. Hiroyuki Nishiyama, et al. Negative regulation of G1/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene 2001;20:2956-2964.
18. A Lopez-Beltran, et al. Loss of heterozygosity at 9q32–33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J Pathol 2008;215:263-272.
19. Eric J Gratias, et al. Gain of 1q is Associated with Inferior Event-Free and Overall Survival in Favorable Histology Wilms Tumor: A Report from the Children’s Oncology Group. Cancer 2013;119:3887-3894.
20. H Kuniyasu, et al. Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas. Int J Cancer 1994;59:59-600.
21. Poetsch M, et al. Loss of heterozygosity at 15q21.3 correlates with occurrence of metastases in head and neck cancer. Mod Pathol 2006;19(11):1462-9.
22. Rhiem K, et al. Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. Int J Cancer 2003;106(1):74-7.
23. Evert Jan Van Limbergen, et al. FLT1 kinase is a mediator of radioresistance and survival in head and neck squamous cell carcinoma. Acta Oncol 2014;53:637-645.
24. Bin-Zhi Qian, et al. FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. J Exp Med 2015;212:1433-1448.
25. Vainchenker W, et al. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32:2601-13.
26. Chloe James, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005;434: 1144-8.
27. Alexandra Wolf, et al. JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells. JAKSTAT 2013;2;e24574.
28. Li F, et al. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res 2019;25(7):2264-2277.
29. Kurimchak A M, et al. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer. Mol Cancer Res 2019;17(8):1721-1734.
30. Sophie M. Stief, et al. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia 2020;34:50-62.